Celebrating a Storied History: Moscow Preobrazhenskaya Mental Hospital Marks its 245 Anniversary.

In 2022, Mental-health Clinic No. 4 named after P. B.

[Comprehensive treatment of adynamic depression with the combined use of traditional psychopharmacotherapy, transcranial magnetic stimulation and virtual reality technologies].

Objective: To study the efficacy and safety of activity-dependent neuromodulation using transcranial magnetic stimulation with intermittent theta flashes (iTBS) as priming stimulation with multimodal parameters of the virtual environment (VR) for the treatment of adynamic depression in comparison with psychopharmacotherapy (PFT).

Material And Methods: The comparative study included 85 patients with adynamic depression who were randomized into four groups: iTBS + VR + PFT (=19), iTBS + PFT (=19), VR + PFT (=23), PFT (=24). The duration of therapy was 20 days, the procedures were carried out daily, with a break for weekends, followed by an assessment of side-effects and control over compliance with the patient's drinking regimen.

[Questions of primary diagnosis of schizophrenia in middle-aged and older patients].

Objective: An analysis of clinical and social characteristics of patients aged 40 years and older with primary diagnosis of schizophrenia (F 20-21) in a psychiatric hospital.

Material And Methods: We studied 114 medical records of patients aged 40 and over who were admitted to a psychiatric hospital for a two-year period (2018-2019) with a first-time diagnosis of schizophrenia (F 20-21) based on the results of inpatient examination and treatment.

Results: The analysis shows that 90% of patients were aged 40-59 years, 59.

[Transfer from paliperidone of one-month action to paliperidone of three-month action in schizophrenia spectrum disorders: clinical aspects, pharmacological strategies, therapeutic prediction].

Objective: To analyze clinical and therapeutic features of the transfer of patients with schizophrenia spectrum disorders from paliperidone palmitate of one-month action (PP-1M) to paliperidone of three-month action (PP-3M).

Material And Methods: Data on the psychopharmacological therapy regimens of 677 patients with verified diagnoses of schizophrenia spectrum disorders (F20, F21, F25) treated with PP-3M drugs after PP-1M therapy were studied.

Results: The study showed the high efficacy of ultra-long-acting paliperidone therapy in 82.

Analysis of influence of background therapy for comorbidities in the period before infection on the risk of the lethal COVID outcome. Data from the international ACTIV SARS-CoV-2 registry («Analysis of chronic non-infectious diseases dynamics after COVID-19 infection in adult patients SARS-CoV-2»).

Aim      To study the effect of regular drug therapy for cardiovascular and other diseases preceding the COVID-19 infection on severity and outcome of COVID-19 based on data of the ACTIVE (Analysis of dynamics of Comorbidities in paTIents who surVived SARS-CoV-2 infEction) registry.Material and methods  The ACTIVE registry was created at the initiative of the Eurasian Association of Therapists. The registry includes 5 808 male and female patients diagnosed with COVID-19 treated in a hospital or at home with a due protection of patients' privacy (data of nasal and throat smears; antibody titer; typical CT imaging features).